TrialThorax2012
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
J P Clancy et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
243 papers cite itlatest 60 shown
this paperpooled ittrialcites it